Alberto
Carmona Bayonas
Asociado Ciencias de la Salud
![Foto de Alberto](/img/uploaded/c9d7750ad373785985563925a999eee0.jpeg)
![Foto de Hospital Vall d'Hebron](/img/noimage_org.png)
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (30)
2023
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
2022
-
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
European Journal of Internal Medicine, Vol. 100, pp. 33-45
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
The oncologist, Vol. 27, Núm. 4, pp. e328-e339
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2021
-
Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study
Cancers, Vol. 13, Núm. 18
-
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)
Health and Quality of Life Outcomes, Vol. 19, Núm. 1
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
2020
-
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
PloS one, Vol. 15, Núm. 7, pp. e0235848
2019
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
-
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
Oncologist, Vol. 24, Núm. 8, pp. e687-e695
-
SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 75-86
2018
-
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism
Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 230-242
2017
-
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience
Future Oncology, Vol. 13, Núm. 7, pp. 615-624
-
Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study
European Respiratory Journal, Vol. 49, Núm. 1
-
Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors
Current Oncology Reports, Vol. 19, Núm. 11
-
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395
-
Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: The EPIPHANY Index
British Journal of Cancer, Vol. 116, Núm. 8, pp. 994-1001